North America
Kyowa Kirin Launches New Efforts to Educate and Engage Physicians and Patients with Rare Forms of Cutaneous T-Cell Lymphoma About Treatment with POTELIGEO® (mogamulizumab-kpkc)
- Treat the Blood. Treat the Skin. physician campaign reinforces importance of regular blood monitoring and a tailored treatment approach in mycosis fungoides and Sézary syndrome
- POTELIGEO ambassadors address patients' need to learn from others with similar, rare diagnosis(1)
BEDMINSTER, N.J., Sept. 23, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the launch of two efforts focused on increasing understanding of mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL),2 and the role of POTELIGEO® (mogamulizumab-kpkc) in treating them.3 Aimed at physicians, the new Treat the Blood. Treat the Skin. omni-channel campaign seeks to educate about the importance of measuring and monitoring blood involvement to inform treatment and potentially impact patient outcomes in MF and
23 September 2021
